Drug Delivery Formulations For Targeted Delivery
The size and location of microsphere uptake/delivery are important determinants of the final biodistribution of oral microsphere systems. Formulations, kits, methods of administering the formulations, and using the kits are described herein. The formulations are oral dosage formulations. In one embodiment, the formulations contain microparticles and/or nanoparticles having a homogenous size range selected to optimize uptake in a specific region of the GI tract and target drug delivery to specific organs. In some embodiments, the dosage formulation contains an enteric coating and/or a magnetic material. In a preferred embodiment, the formulation contains a magnetic material and an active agent to be delivered, optionally the active agent is in the form of micro- or nano-particles. In some embodiments metallomucoadhesive materials and/or magnetic materials are employed as magnetic and/or mucoadhesive sources. Formulations containing magnetic materials can be localized using the kits and methods disclosed herein. In one embodiment, the method includes orally administering the formulation and applying an extracorporeal magnet to a site on the outside surface of the patient's body in an area that closely apposes the location in the gastrointestinal tract to which delivery of the formulation is desired. The extracorporeal magnet is applied for a suitable time period to allow for the drug to be released from the formulation and/or to allow for the formulation to adhere to the site. Both magnetic and mucoadhesive forces may be utilized to site-direct and retain the dosage form in the region of the gastrointestinal (GI) tract most suitable for the desired delivery.
1 . An oral dosage formulation for enhanced relative delivery of a therapeutic, prophylactic or diagnostic agent to the lymphatic capillaries comprising
microparticles containing the therapeutic, prophylactic or diagnostic agent to be delivered, in the form of a homogenous population wherein preferably 75% of the microparticles have a mean diameter of about 1 or 0.5 micron.
2 . (canceled)
3 . The formulation of claim 1 , further comprising a metallomucoadhesive or magnetic material.
4 . The formulation of claim 3 , wherein the metallomucoadhesive material is selected from the group consisting of chromium and its oxides, iron and its oxides, titanium and its oxides, aluminum and its oxides, nickel and its oxides, zinc and its oxides, neodymium and its oxides, gold, silver and its oxides and salts, copper and its oxides, and alloys thereof.
5 . The formulation of claim 3 , wherein the magnetic material is a ferromagnetic or superparamagnetic compound.
6 . The formulation of claim 5 , wherein the magnetic material is selected from the group consisting of martensitic stainless steels, iron oxides, neodymium iron boron ceramic, alnico (AlNiCo), and samarium cobalt.
7 . The formulation of claim 1 , wherein the formulation is a solid oral dosage formulation.
8 . The formulation of claim 1 , wherein the formulation further comprises an enteric coating.
9 . A method for enhanced relative delivery of a therapeutic, prophylactic or diagnostic agent to the lymphatic system comprising
orally administering to a patient in need thereof the formulation of claim 1 to the ileum.
10 . The method of claim 9 , further comprising applying an extracorporeal magnet to the outside surface of the patient's body at a site in an area that apposes the ileum.
11 . The method of claim 10 , further comprising removing the extracorporeal magnet from the site after a period of time effective to attach the formulation to the ileum via mucoadhesive forces.
12 . The method of claim 11 , wherein the period of time ranges from 1 to 8 hours.
13 . The method of claim 10 , further comprising removing the extracorporeal magnet from the site after a period of time effective to attach the formulation to the ileum via Mucoadhesive forces release.
14 . The method of claim 12 , wherein the period of time ranges from 5 minutes to 24 hours.
15 . A method for enhanced relative delivery of a therapeutic, prophylactic or diagnostic agent to the portal circulation and liver comprising
orally administering to a patient in need thereof the formulation of 2 to the jejenum.
16 . The method of claim 15 , further comprising applying an extracorporeal magnet to the outside surface of the patient's body at a site in an area that apposes the jejunum.
17 . The method of claim 16 , further comprising removing the extracorporeal magnet from the site after a period of time effective to attach the formulation to the jejunum via mucoadhesive forces.
18 . The method of claim 17 , wherein the period of time ranges from 1 to 8 hours.
19 . The method of claim 16 , further comprising removing the extracorporeal magnet from the site after a period of time effective to release the therapeutic, prophylactic or diagnostic agent from the formulation.
20 . The method of claim 19 , wherein the period of time ranges from 5 minutes to 24 hours.
21 . An oral dosage formulation for enhanced relative delivery of a therapeutic, prophylactic or diagnostic agent to a site within the gastrointestinal tract comprising
the therapeutic, prophylactic or diagnostic agent to be delivered and a magnetic material.
22 . The formulation of claim 21 , wherein the formulation is a solid oral dosage formulation in a form selected from the group consisting of tablets, capsules, and osmotic-pump-based delivery systems.
23 . A kit comprising an oral dosage formulation of claim 1 and an extracorporeal magnet.
24 . A method for enhanced uptake of a therapeutic, prophylactic or diagnostic agent to a site in the gastrointestinal tract comprising
selecting a site in the gastrointestinal tract for delivery of the therapeutic, prophylactic or diagnostic agent,
orally administering to a patient in need thereof the formulation of claim 21 , and
applying an extracorporeal magnet to the outside surface of the patient's body at a second site in an area that apposes the selected site in the gastrointestinal tract.
25 . The method of claim 24 , further comprising removing the extracorporeal magnet from the second site after a period of time effective to attach the formulation to the selected site via mucoadhesive forces.
26 . The method of claim 25 , wherein the period of time ranges from 1 to 8 hours.
27 . The method of claim 24 , further comprising removing the extracorporeal magnet from the second site after a period of time effective to release the therapeutic, prophylactic or diagnostic agent from the formulation.
28 . The method of claim 26 , wherein the period of time ranges from 5 minutes to 24 hours.